DA32 Life Science Tech Acquisition Corp.
DA32 Life Science Tech Acquisition Corp.
Share · US23312M1062 · DALS (XNAS)
Overview
No Price
n/a
Share Float & Liquidity
Free Float -
Shares Float -
Shares Outstanding 25,65 M
Company Profile for DA32 Life Science Tech Acquisition Corp. Share
DA32 Life Science Tech Acquisition Corp. does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. The company intends to identify business combination targets in the biotechnology and life science infrastructure sectors. DA32 Life Science Tech Acquisition Corp. was incorporated in 2021 and is based in New York, New York.
Get up to date insights from finAgent about DA32 Life Science Tech Acquisition Corp.

Company Data

Name DA32 Life Science Tech Acquisition Corp.
Company DA32 Life Science Tech Acquisition Corp.
Symbol DALS
Primary Exchange XNAS NASDAQ
ISIN US23312M1062
Asset Class Share
Sector Financial Services
Industry Shell Companies
CEO Steven Kafka
Market Capitalization 264 Mio
Country United States of America
Currency USD
Employees -
Address 345 Park Avenue South, 10010 New York City
IPO Date 2021-07-28

Ticker Symbols

Name Symbol
NASDAQ DALS
More Shares
Investors who hold DA32 Life Science Tech Acquisition Corp. also have the following shares in their portfolio:
AMUNDI FUNDS GLOBAL AGGREGATE BOND - I EUR HGD AD (D)
AMUNDI FUNDS GLOBAL AGGREGATE BOND - I EUR HGD AD (D) ETF
Vanguard Emerging Markets Select Stock Fund Investor Shares
Vanguard Emerging Markets Select Stock Fund Investor Shares Fund
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025